Fluorouracil News and Research

RSS
Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.
Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron reports total revenues of $123.0M for fourth quarter 2011

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Mylan acquires two dermatological drugs from Valeant

Mylan acquires two dermatological drugs from Valeant

Valeant divests generic Benzaclin and Efudex to Mylan

Valeant divests generic Benzaclin and Efudex to Mylan

Combination of Toca 511 and 5-FC may prolong survival in glioblastoma

Combination of Toca 511 and 5-FC may prolong survival in glioblastoma

Adding oxaliplatin to adjuvant 5FU improves survival of patients with stage III colon cancer

Adding oxaliplatin to adjuvant 5FU improves survival of patients with stage III colon cancer

Saladax increases claims in immunoassay space to 15 patents

Saladax increases claims in immunoassay space to 15 patents

Combination of bevacizumab and chemoradiation safe, effective for nasopharyngeal carcinoma

Combination of bevacizumab and chemoradiation safe, effective for nasopharyngeal carcinoma

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen receives EC approval to extend therapeutic indications for Vectibix

Idera third quarter net loss increases to $5.5 million

Idera third quarter net loss increases to $5.5 million

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Saladax, Bristol-Myers Squibb expand Alzheimer's diagnostic assays agreement

Saladax, Bristol-Myers Squibb expand Alzheimer's diagnostic assays agreement

Researchers identify promising new therapies for ependymoma

Researchers identify promising new therapies for ependymoma

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

Kaan Medikal to distribute Saladax's My5-FU diagnostic test in Turkey

Kaan Medikal to distribute Saladax's My5-FU diagnostic test in Turkey

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer